Purpose: Gemcitabine is currently the standard first-line chemotherapeutic agent for
pancreatic cancer. However, chemoresistance to gemcitabine because of gemcitabine …

In this study, we assessed if nafamostat mesilate may enhance anti-tumor effects of
oxaliplatin on Panc-1 cells and pancreatic cancer mouse model. In combination treatment …

Constitutive NF-κB activation plays a key role in the aggressive behavior of pancreatic
cancer. We have reported that nafamostat mesilate, a serine-protease inhibitor, inhibited NF …

Introduction Gemcitabine is standard treatment for pancreatic cancer but has limited clinical
benefit due to chemoresistance. Nuclear factor-kappaB (NF-κB) can promote …

Background Constitutive activation of nuclear factor kappa-B (NF-κB) contributes to the
aggressive behavior of pancreatic cancer. Over-expression of downstream target genes of …

First-line therapy for pancreatic cancer is gemcitabine. Although tumors may initially respond
to the gemcitabine treatment, soon tumor resistance develops leading to treatment failure …

Previous studies have shown biological activity of thymoquinone, an active compound
extracted from Nigella sativa, in pancreatic cancer cells; however, preclinical animal studies …

The current performance of nature compounds in antitumor field is gradually attracted more
and more attention, we discovered a nature active ingredient alizarin possess potent natural …

Background Pancreatic cancer remains one of the deadliest cancers due to lack of early
detection and absence of effective treatments. Gemcitabine, the current standard-of-care …

Pancreatic cancer is an aggressive malignancy, which generally respond poorly to
chemotherapy. Hence, novel agents that are safe and effective are highly needed. The aim …